Several neurodegenerative diseases begin when toxic protein clumps form in neurons. Scientists have yet to find a good way to clear these clumps from cells. Researchers now report that a ...

An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...

(A, B) The qRT-PCR results showed increased mRNA expression of HBEGF, EREG, and AREG induced by Yoda1 in endothelial cells and was reversed with Piezo1 knockdown in HUVEC cells. (C, D) the ELISA assay ...

Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...

In animal models, the experimental compound IkT-148009, an inhibitor of Abelson’s tyrosine kinase (c-Abl), prevented the accumulation of the misfolded protein α-synuclein, which is associated with ...

- Preclinical research and clinical safety and tolerability data supports continued development of IkT-148009 to potentially slow or halt progression of Parkinson's disease BOSTON and ATLANTA, Nov. 29 ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...

Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute ...